Declining Sales of Long-Listed Products Due to Category Changes
First written in FY2017-Q1. 16 of 18 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2018: 20 of 65 companies on the "Worse" side.
48 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「As blockbuster drugs lose patent protection and the use of generic drugs is promoted, the focus of newly launched drugs is shifting toward specialty pharmaceuticals. This is increasing the need for pharmaceutical wholesalers to enhance their capabilities in information provision and logistics.」
It reaffirms the challenges associated with blockbuster drugs losing patent protection, the promotion of generic drug use, and the shift toward specialty pharmaceuticals. - FY2026-H1RestatedAnnual report
「As blockbuster drugs lose patent protection and the use of generic drugs is promoted, the focus of newly launched drugs is shifting toward specialty pharmaceuticals. This is increasing the need for pharmaceutical wholesalers to enhance their capabilities in information provision and logistics.」
It reaffirms the structural changes resulting from blockbuster drugs losing patent protection and the promotion of generic drug use, and indicates the need to enhance information provision and logistics capabilities as the market shifts toward specialty pharmaceuticals. - FY2022WorsenedAnnual report
「In particular, although the volume of off-patent products, including long-listed products and generic products, may increase substantially, product unit prices are expected to decline faster than before due to revisions to the drug pricing system and annual drug price revisions, causing revenue to decline rapidly.」
It indicates that, for long-listed and generic products, product unit prices will decline faster than before even if volumes increase, resulting in a rapid decline in revenue. - FY2020RestatedAnnual report
「The April 2018 revision to the medical service fee schedule also introduced further measures to promote the use of generic drugs, and sales of long-listed products continued to decline during the consolidated fiscal year.」
Declining sales of long-listed products against the backdrop of measures promoting the use of generic drugs continued throughout the full year. - FY2020-Q3RestatedAnnual report
「In the pharmaceutical wholesale business, sales of long-listed products had already been declining due to product-category shifts, and the April 2018 revision to the medical service fee schedule introduced further measures to promote the use of generic drugs. Sales of long-listed products continued to decline during the cumulative consolidated period.」
It states that declining sales of long-listed products against the backdrop of measures promoting the use of generic drugs continued during the cumulative third-quarter period. - FY2020-Q2RestatedAnnual report
「In the pharmaceutical wholesale business, sales of long-listed products had already been declining due to product-category shifts, and the April 2018 revision to the medical service fee schedule introduced further measures to promote the use of generic drugs. Sales of long-listed products continued to decline during the cumulative second-quarter period.」
Declining sales of long-listed products against the backdrop of measures promoting the use of generic drugs continued during the cumulative second-quarter period. - FY2020-Q1RestatedAnnual report
「In the pharmaceutical wholesale business, sales of long-listed products had already been declining due to product-category shifts, and the April 2018 revision to the medical service fee schedule introduced further measures to promote the use of generic drugs. Sales of long-listed products continued to decline during the cumulative consolidated period.」
Because the decline in long-listed product sales has continued in practice, materialized is determined to be true. - FY2020-Q1RestatedAnnual report
「In the pharmaceutical wholesale business, sales of long-listed products had already been declining due to product-category shifts, and the April 2018 revision to the medical service fee schedule introduced further measures to promote the use of generic drugs. Sales of long-listed products continued to decline during the cumulative consolidated period.」
Declining sales of long-listed products against the backdrop of measures promoting the use of generic drugs continued during the cumulative first-quarter period. - FY2019RestatedAnnual report
「The April 2018 revision to the medical service fee schedule also introduced further measures to promote the use of generic drugs, and sales of long-listed products continued to decline during the cumulative consolidated period.」
Declining sales of long-listed products against the backdrop of measures promoting the use of generic drugs continued throughout the full year. - FY2019-Q3RestatedAnnual report
「In the pharmaceutical wholesale business, sales of long-listed products had already been declining due to product-category shifts, and the April 2018 revision to the medical service fee schedule introduced further measures to promote the use of generic drugs. Sales of long-listed products continued to decline during the cumulative consolidated period.」
It states that declining sales of long-listed products against the backdrop of measures promoting the use of generic drugs continued during the cumulative third-quarter period. - FY2019-Q2RestatedAnnual report
「In the pharmaceutical wholesale business, sales of long-listed products had already been declining due to product-category shifts, and the April 2018 revision to the medical service fee schedule introduced further measures to promote the use of generic drugs. Sales of long-listed products continued to decline during the cumulative consolidated period.」
Declining sales of long-listed products against the backdrop of measures promoting the use of generic drugs continued during the cumulative second-quarter period. - FY2018RestatedAnnual report
「The April 2018 revision to the medical service fee schedule also introduced further measures to promote the use of generic drugs, and sales of long-listed products continued to decline.」
Declining sales of long-listed products against the backdrop of measures promoting the use of generic drugs continued. - FY2018-Q3RestatedAnnual report
「Sales of long-listed products had already been declining due to product-category shifts, and the April 2016 revision to the medical service fee schedule introduced further measures to promote the use of generic drugs. Sales of long-listed products continued to decline during the cumulative third-quarter period.」
Declining sales of long-listed products against the backdrop of measures promoting the use of generic drugs continued during the cumulative third-quarter period. - FY2018-Q2RestatedAnnual report
「Sales of long-listed products had already been declining due to product-category shifts, and the April 2016 revision to the medical service fee schedule introduced further measures to promote the use of generic drugs. Sales of long-listed products continued to decline during the cumulative second-quarter period.」
Declining sales of long-listed products against the backdrop of measures promoting the use of generic drugs continued during the cumulative second-quarter period. - FY2018-Q1RestatedAnnual report
「Sales of long-listed products had already been declining due to product-category shifts, and the April 2016 revision to the medical service fee schedule introduced further measures to promote the use of generic drugs. Sales of long-listed products continued to decline during the cumulative consolidated period.」
It states that declining sales of long-listed products against the backdrop of measures promoting the use of generic drugs continued in the first-quarter cumulative period. - FY2017RestatedAnnual report
「Sales of long-listed products had been declining due to product-category shifts, and the April 2016 revision to the medical service fee schedule introduced further measures to promote the use of generic drugs. Sales of long-listed products continued to decline during the consolidated fiscal year.」
It states that declining sales of long-listed products against the backdrop of measures promoting the use of generic drugs continued throughout the full year. - FY2017-Q2RestatedAnnual report
「Sales of long-listed products had already been declining due to product-category shifts, and the April 2016 revision to the medical service fee schedule introduced further measures to promote the use of generic drugs. Sales of long-listed products continued to decline during the cumulative second-quarter period.」
It states that declining sales of long-listed products driven by measures promoting the use of generic drugs continued in the first half. - FY2017-Q1First statedAnnual report
「Sales of long-listed products had already been declining due to product-category shifts, and the April 2016 revision to the medical service fee schedule introduced further measures to promote the use of generic drugs. Sales of long-listed products continued to decline during the cumulative consolidated period.」
The business impact of continued declines in long-listed product sales against the backdrop of measures promoting the use of generic drugs is described.